• Explore /
  • Poster
  • / Analysis of <em>RAS</em>/<em>BRAF</em> mutations in a randomized phase II WJOG6510G study of panitumumab plus irinotecan versus cetuximab plus irinotecan in chemorefractory metastatic colorectal cancer.

Analysis of RAS/BRAF mutations in a randomized phase II WJOG6510G study of panitumumab plus irinotecan versus cetuximab plus irinotecan in chemorefractory metastatic colorectal cancer.

Abstract Poster

Authors

null

Tomohiro Nishina

Shikoku Cancer Center, Matsuyama, Japan

Tomohiro Nishina , Hiroya Taniguchi , Daisuke Sakai , Hisato Kawakami , Naotoshi Sugimoto , Hiroki Hara , Taito Esaki , Tadamichi Denda , Akitaka Makiyama , Masahiro Tsuda , Hiroyuki Okuda , Naoki Izawa , Ayumu Hosokawa , Kentaro Yamazaki , Shinya Tokunaga , Toshikazu Moriwaki , Akihito Tsuji , Yasuhiro Koh , Junji Kishimoto , Kei Muro

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Translational Research

Clinical Trial Registration Number

UMIN000006643

Citation

J Clin Oncol 36, 2018 (suppl 4S; abstr 624)

DOI

10.1200/JCO.2018.36.4_suppl.624

Abstract #

624

Poster Bd #

D9

Abstract Disclosures

Similar Posters

First Author: Samuel A. Jacobs

First Author: John H. Strickler

First Author: Kohei Shitara

First Author: Ann-Lii Cheng